UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 854

Sortiert nach

RECIST revisited: A review of validation studies on tumour assessment

European journal of cancer (1990), 2006-05, Vol.42 (8), p.1031-1039

2006

Volltextzugriff (PDF)

Real-world evidence in the treatment of ovarian cancer

Annals of oncology, 2017-11, Vol.28 (suppl_8), p.viii61-viii65

Eisenhauer, E A

2017

Volltextzugriff (PDF)

A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study

Annals of oncology, 2011-02, Vol.22 (2), p.335-340

2011

Volltextzugriff (PDF)

A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150

Annals of oncology, 2007-01, Vol.18 (1), p.116-121

2007

Volltextzugriff (PDF)

Advanced Ovarian Cancer: Phase III Randomized Study of Sequential Cisplatin–Topotecan and Carboplatin–Paclitaxel vs Carboplatin–Paclitaxel

JNCI : Journal of the National Cancer Institute, 2010-10, Vol.102 (20), p.1547-1556

2010

Volltextzugriff (PDF)

Response evaluation: beyond RECIST

Annals of oncology, 2007-07, Vol.18 (suppl-9), p.ix29-ix32

Eisenhauer, EA

2007

Volltextzugriff (PDF)

Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179)

Annals of oncology, 2012-01, Vol.23 (1), p.238-244

2012

Volltextzugriff (PDF)

Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours

British journal of cancer, 2011-03, Vol.104 (5), p.756-762

2011

Volltextzugriff (PDF)

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

European journal of cancer (1990), 2009-01, Vol.45 (2), p.228-247

2009

Volltextzugriff (PDF)

Phase I Trial Design for Solid Tumor Studies of Targeted, Non-Cytotoxic Agents: Theory and Practice

JNCI : Journal of the National Cancer Institute, 2004-07, Vol.96 (13), p.990-997

2004

Volltextzugriff (PDF)

Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study

Annals of oncology, 2011-11, Vol.22 (11), p.2403-2410

2011

Volltextzugriff (PDF)

Anticancer Agents Targeting Signaling Molecules and Cancer Cell Environment:Challenges for Drug Development?

JNCI : Journal of the National Cancer Institute, 1999-08, Vol.91 (15), p.1281-1287

1999

Volltextzugriff (PDF)

Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariate analysis of 704 patients

Annals of oncology, 1997-10, Vol.8 (10), p.963-968

1997

Volltextzugriff (PDF)

Phase I and II trials of novel anti-cancer agents : Endpoints, efficacy and existentialism : The Michel Clavel lecture, held at the 10th NCI-EORTC Conference on New Drugs in Cancer Therapy, Amsterdam, 16-19 June 1998

Annals of oncology, 1998-10, Vol.9 (10), p.1047-1052

EISENHAUER, E. A

1998

Volltextzugriff (PDF)

Performance of multinomial designs in comparison with response-based designs in non-randomized phase II trials of targeted cancer agents

Annals of oncology, 2013-07, Vol.24 (7), p.1936-1942

2013

Volltextzugriff (PDF)

Phase I Clinical Trial Design in Cancer Drug Development

Journal of clinical oncology, 2000-02, Vol.18 (3), p.684-692

2000

Volltextzugriff (PDF)

The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects

British Journal of Cancer, 1999-05, Vol.80 (5-6), p.629-638

1999

Volltextzugriff (PDF)

Evaluation of lymph nodes with RECIST 1.1

European journal of cancer (1990), 2009-01, Vol.45 (2), p.261-267

2009

Volltextzugriff (PDF)

A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly

Annals of oncology, 2003-05, Vol.14 (5), p.766-774

2003

Volltextzugriff (PDF)

European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion

Journal of clinical oncology, 1994-12, Vol.12 (12), p.2654-2666

1994

Volltextzugriff (PDF)

Early integration of palliative care into standard oncology care: evidence and overcoming barriers to implementation

Current oncology (Toronto), 2016-12, Vol.23 (6), p.374-377

2016

Volltextzugriff (PDF)

The taxoids : Comparative clinical pharmacology and therapeutic potential

Drugs (New York, N.Y.), 1998, Vol.55 (1), p.5-30

1998

Volltextzugriff (PDF)

Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199)

Gynecologic oncology, 2013-08, Vol.130 (2), p.269-274

2013

Volltextzugriff (PDF)

Current perspectives on camptothecins in cancer treatment

British journal of cancer, 1996-08, Vol.74 (3), p.327-338

1996

Volltextzugriff (PDF)

Optimal assessment of response in ovarian cancer

Annals of oncology, 2011-12, Vol.22 Suppl 8, p.viii49-viii51

Eisenhauer, E A

2011

Volltextzugriff (PDF)

1 – 25 von 854

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(792)
Mit Volltextzugriff
(775)

Publikationsform

5 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(512)
Life Sciences & Biomedicine
(394)
Humans
(319)
Female
(234)
Oncology
(218)
Biological And Medical Sciences
(190)
Middle Aged
(169)
Medical Sciences
(166)
Aged
(152)
Adult
(140)
Male
(134)
Pharmacology. Drug Treatments
(126)
Physical Sciences
(118)
Chemotherapy
(112)
Antineoplastic Agents
(105)
Antineoplastic Agents - Therapeutic Use
(66)
Hematology, Oncology And Palliative Medicine
(65)
Treatment Outcome
(63)
Astronomy & Astrophysics
(62)
Ovarian Cancer
(52)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

RECIST revisited: A review of validation studies on tumour assessment

Real-world evidence in the treatment of ovarian cancer

A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study

A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150

Advanced Ovarian Cancer: Phase III Randomized Study of Sequential Cisplatin–Topotecan and Carboplatin–Paclitaxel vs Carboplatin–Paclitaxel

Response evaluation: beyond RECIST

Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179)

Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

Phase I Trial Design for Solid Tumor Studies of Targeted, Non-Cytotoxic Agents: Theory and Practice

Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study

Anticancer Agents Targeting Signaling Molecules and Cancer Cell Environment:Challenges for Drug Development?

Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariate analysis of 704 patients

Phase I and II trials of novel anti-cancer agents : Endpoints, efficacy and existentialism : The Michel Clavel lecture, held at the 10th NCI-EORTC Conference on New Drugs in Cancer Therapy, Amsterdam, 16-19 June 1998

Performance of multinomial designs in comparison with response-based designs in non-randomized phase II trials of targeted cancer agents

Phase I Clinical Trial Design in Cancer Drug Development

The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects

Evaluation of lymph nodes with RECIST 1.1

A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly

European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion

Early integration of palliative care into standard oncology care: evidence and overcoming barriers to implementation

The taxoids : Comparative clinical pharmacology and therapeutic potential

Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199)

Current perspectives on camptothecins in cancer treatment

Optimal assessment of response in ovarian cancer

Suchergebnisse filtern